Sign in Register

Drug class

Antiviral-HIV (Antiretroviral) CCR5 Co-Receptor Antagonist

The antiviral-HIV CCR5 co-receptor antagonist class is a specialized group of antiretroviral entry inhibitors used in combination regimens to treat human immunodeficiency virus type 1 (HIV-1) infection. Read more about Antiviral-HIV (Antiretroviral) CCR5 Co-Receptor Antagonist

9 drugs in this class 7 manufacturers

Related classes & indications

Antimalarial DrugsAnti-infectives · 223 prescription drugs Antiprotozoal AgentsAnti-infectives · 102 prescription drugs Ccr5 Tropic Hiv InfectionTop indication · 9 prescription drugs

Showing 1–9 of 9 drugs

Sort

SELZENTRY (maraviroc)

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST · CCR5 TROPIC HIV INFECTION

VIIV HEALTHCARE

SELZENTRY (maraviroc)

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST · CCR5 TROPIC HIV INFECTION

VIIV HEALTHCARE

MARAVIROC

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST · CCR5 TROPIC HIV INFECTION

CAMBER PHARMACE

SELZENTRY (maraviroc)

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST · CCR5 TROPIC HIV INFECTION

A-S MEDICATION

MARAVIROC

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST · CCR5 TROPIC HIV INFECTION

I3 PHARMACEUTIC

MARAVIROC

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST · CCR5 TROPIC HIV INFECTION

XLCARE PHARMACE

MARAVIROC

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST · CCR5 TROPIC HIV INFECTION

A2A INTEGRATED

MARAVIROC

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST · CCR5 TROPIC HIV INFECTION

ZYDUS PHARMACEU

MARAVIROC

ANTIVIRAL-HIV (ANTIRETROVIRAL) CCR5 CO-RECEPTOR ANTAGONIST · CCR5 TROPIC HIV INFECTION

A-S MEDICATION

Filter & compare in the drug finder → Opens the drug finder with Antiviral-HIV (Antiretroviral) CCR5 Co-Receptor Antagonist preselected. Add indication or manufacturer filters there.

About Antiviral-HIV (Antiretroviral) CCR5 Co-Receptor Antagonist.

The antiviral-HIV CCR5 co-receptor antagonist class is a specialized group of antiretroviral entry inhibitors used in combination regimens to treat human immunodeficiency virus type 1 (HIV-1) infection.

Rather than targeting viral enzymes, these agents selectively bind to the host cell surface chemokine receptor CCR5, blocking its interaction with viral envelope glycoprotein gp120 and preventing CCR5-tropic virions from fusing with and entering host CD4 T cells.

This drug class is primarily indicated for patients with documented CCR5-tropic HIV-1, frequently serving as an essential therapeutic option for treatment-experienced individuals harboring viral strains resistant to other antiretroviral classes.

Because their activity is strictly receptor-dependent, they lack efficacy against CXCR4-tropic or dual-tropic viral strains.

fda.gov
The antiviral-HIV CCR5 co-receptor antagonist class is a specialized group of antiretroviral entry inhibitors used in combination regimens to treat human immunodeficiency virus type 1 (HIV-1) infection
fda.gov
The antiviral-HIV CCR5 co-receptor antagonist class is a specialized group of antiretroviral entry inhibitors used in combination regimens to treat human immunodeficiency virus type 1 (HIV-1) infection Because their activity is strictly receptor-dependent, they lack efficacy against CXCR4-tropic or dual-tropic viral strains
fda.gov
Rather than targeting viral enzymes, these agents selectively bind to the host cell surface chemokine receptor CCR5, blocking its interaction with viral envelope glycoprotein gp120 and preventing CCR5-tropic virions from fusing with and entering host CD4 T cells Because their activity is strictly receptor-dependent, they lack efficacy against CXCR4-tropic or dual-tropic viral strains
nih.gov
Rather than targeting viral enzymes, these agents selectively bind to the host cell surface chemokine receptor CCR5, blocking its interaction with viral envelope glycoprotein gp120 and preventing CCR5-tropic virions from fusing with and entering host CD4 T cells
nih.gov
Rather than targeting viral enzymes, these agents selectively bind to the host cell surface chemokine receptor CCR5, blocking its interaction with viral envelope glycoprotein gp120 and preventing CCR5-tropic virions from fusing with and entering host CD4 T cells
fda.gov
This drug class is primarily indicated for patients with documented CCR5-tropic HIV-1, frequently serving as an essential therapeutic option for treatment-experienced individuals harboring viral strains resistant to other antiretroviral classes
fda.gov
This drug class is primarily indicated for patients with documented CCR5-tropic HIV-1, frequently serving as an essential therapeutic option for treatment-experienced individuals harboring viral strains resistant to other antiretroviral classes Because their activity is strictly receptor-dependent, they lack efficacy against CXCR4-tropic or dual-tropic viral strains